ZURA · Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Market Cap
99.7M
52 Wk Range
$0.93 - $7.44
Previous Close
$1.04
Open
$1.01
Volume
3,017,069
Day Range
$0.94 - $1.05
Enterprise Value
-84.1M
Cash
187.7M
Avg Qtr Burn
-19.5M
Insider Ownership
18.83%
Institutional Own.
82.15%
Qtr Updated
Sep 30th 2026
